JPRN-UMIN000010254已完成未知
Phase 1 study of sulfapyridine in patients with advanced gastric cancer. - SASP
ational Cancer Center Hospital East0 个研究点目标入组 6 人开始时间: 2013年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Chemotherapy, radiation therapy or other investigational drugs within 2 weeks prior to enrollment. 2) Active bleeding. 3) Patient with any of the following symptoms within 6 months prior to administration of the drug; myocardial infarction, severe or unstable angina, congested heart failure, cerebrovascular accident containing transient ischemic attack or pulmonary embolism. 4) Uncontrolled bronchial asthma. 5) Patient with brain metastases. 6) Laparotomy or thoracotomy within 4 weeks to enrollment. 7) Known hypersensitivity to sulfa drugs or acetylsalicylic acid formulation. 8) Women during pregnancy or lactation, women suspected of being pregnant, women desiring future fertility. 9) Patient is judged by the investigator to be inappropriate for study participation for any reason. 10) Patient with Ulcerative colitis, or treated patient with sulfapyridine or 5-ASA derivative.
研究者
相似试验
招募中
1 期
PhaseI/ II study of disulfiram in patients with advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000008529Chiba University Hospital60
尚未招募
1 期
Managment of Emesis Gravidarum in AyurvedaCTRI/2018/05/013602Parul Institute of Ayurved and Hospital
已完成
1 期
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Patients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT1080225320ROHTO PHARMACEUTICAL CO., LTD.6
已完成
不适用
Phase I study of nedaplatin and S-1 in patients with advanced or relapsed squamous cell lung cancerSquamous cell lung cancerJPRN-UMIN000036387Kagawa University9
进行中（未招募）
1 期
A Phase 1 trial of pf-03084014 in patients with advanced solid tumor malignancy and t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma - NDadvanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).MedDRA version: 9.1Level: LLTClassification code 10066110MedDRA version: 9.1Level: LLTClassification code 10065252MedDRA version: 9.1Level: LLTClassification code 10065923EUCTR2010-022036-36-ITPfizer Inc., 235 East 42nd Street, New York, NY 1001760